DEC 19, 2018 05:50 PM PST

Promising Drug for ALS?

WRITTEN BY: Nouran Amin

ALS, standing for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease affecting the nerve cells of the brain and the spinal cord. Current treatments for ALS work by slowing the progression of the disease however by only a few months. Now, research at the University of Alberta shows a promising drug that not only significantly slows the progression of the disease but can revolutionize treatment for ALS patients by extending and improving their quality of life.

Learn more about ALS:

The drug is called telbivudine and is used as a treatment for patients with hepatitis making it particularly safe as a promising therapeutic for ALS. "It is already proven safe to use in patients, and it has very good potential for repurposing to use in a new clinical setting against ALS," said Ted Allison, co-author of the study and associate professor in the Department of Biological Sciences.

In the research study published in Neurobiology of Disease, telbivudine was selected using computer simulations of most likely drug candidates before being tested on animal models. Specifically, the works by targeting a protein called SOD1. The protein was found to misfold and function improperly in ALS producing toxic effects that characterizes much of the phenotypic symptoms of the disease.

Credit: Medical News Today

"SOD1 is a protein that is known to misfold and misbehave in most cases of patients with ALS," says Allison. "We showed that telbivudine can greatly reduce the toxic properties of SOD1, including improving the health of the subject's motor neurons and improving movement."

However, because ALS is still not well understood by researchers and clinicians—promising therapeutics may take a while before being sent to clinical trials. But, this study provides one step closer.

“We don't yet know exactly what goes wrong first in the motor neurons or how the misbehaving SOD1 causes toxicity. Because there is still much to learn about the disease, the ALS research community focuses on both understanding ALS and on developing promising therapies,” explains lead author of the study—Michele DuVal.

Source: University of Alberta

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 13, 2018
Drug Discovery
NOV 13, 2018
Clinical Trial Drug For a Rare Neurodegenrative Disease Proven Unsuccessful
Niemann-Pick type C (NPC) is a rare and fatal neurodegenerative disease. Symptoms of the condition include loss of balance, difficulty swallowing, seizures...
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Anti-inflammatory Drug Works Like an Inhibitor
At Karolinska Institutet in Sweden, a team of scientists from multiple disciplines have worked together to develop an inflammation inhibitor. The new anti-...
NOV 24, 2018
Drug Discovery
NOV 24, 2018
New Anti-Malarial Drug Target in Cancer
For decades, anti-malaria drugs--known as Chloroquines, have used to treat cancer. But the role in repurposing these drugs for slowing tumor growth have ne...
NOV 25, 2018
Drug Discovery
NOV 25, 2018
'Longevity protein' Improves Healing in Aging Muscles
A downside to aging is that the skeletal muscles lose their ability to heal after muscle injury. However, a recent research study at the University of Pitt...
DEC 16, 2018
Health & Medicine
DEC 16, 2018
Important Biomedical Research At Risk Of Being Defunded
In September the Department of Health and Human Services (D.H.H.S.) released a statement citing “serious regulatory, moral and ethical considerations...
DEC 26, 2018
Drug Discovery
DEC 26, 2018
Compound Shrinks Tumors of Sarcoma Cells
According to a multi-disciplinary study carried out by the University of Illinois, a compound was found to effectively shrink tumors in animal models by ta...
Loading Comments...